We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) announced that the European Medical Agency (EMA) has authorized Vaxzevria, its COVID-19 vaccine, for use as a third/booster dose in adults in Europe. A primary two-dose vaccine regimen of Vaxzevria is already authorized for use in the EU.
Vaxzevria is now approved for use as a booster dose in adults who already completed a primary vaccination regimen with Vaxzevria or an mRNA-based COVID-19 vaccine developed by Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Moderna (MRNA - Free Report) , both of which are already approved in the European Union (EU).
The EMA’s authorization follows a positive review by the Committee for Medicinal Products for Human Use (CHMP), which recommended the use of a booster dose of the vaccine. The decisions by both the EMA and CHMP are based on clinical studies, which demonstrated an increase in immune response in participants who were given the booster dose. These participants had already completed a primary two-dose vaccine regimen with Vaxzevria or mRNA-based vaccines approved for use in the European Union (EU).
In the year so far, shares of AstraZeneca have risen 14% compared with the industry’s 5.1% increase.
Image Source: Zacks Investment Research
Excluding the EU, AstraZeneca’s COVID-19 vaccine, either as a primary regimen or a booster dose or both, is already authorized for use in multiple countries across the globe. In fact, the primary vaccine series of the vaccine is granted authorization in more than 125 countries. However, AZN is yet to make a regulatory filing for Vaxzevria in the United States.
Last November, in the United States, the first booster doses of Pfizer/BioNTech and Moderna’s vaccines were granted an EUA for all adults (18 years of age and older). Later, Pfizer/BioNTech’s EUA was extended to allow the dosage in individuals aged 16-17 years and thereafter in adolescents varying from 12 years to 15 years of age. Last week, the Pfizer/BioNTech vaccine was also granted an EUA for use in kids between 5 years and 11 years of age.
In March this year, the FDA authorized a second booster dose of Pfizer/BioNTech and Moderna’s vaccines for older adults and some immunocompromised people. Pfizer/BioNTech and Moderna’s booster shots are authorized for use in adults in Europe.
Image: Bigstock
AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot
AstraZeneca (AZN - Free Report) announced that the European Medical Agency (EMA) has authorized Vaxzevria, its COVID-19 vaccine, for use as a third/booster dose in adults in Europe. A primary two-dose vaccine regimen of Vaxzevria is already authorized for use in the EU.
Vaxzevria is now approved for use as a booster dose in adults who already completed a primary vaccination regimen with Vaxzevria or an mRNA-based COVID-19 vaccine developed by Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Moderna (MRNA - Free Report) , both of which are already approved in the European Union (EU).
The EMA’s authorization follows a positive review by the Committee for Medicinal Products for Human Use (CHMP), which recommended the use of a booster dose of the vaccine. The decisions by both the EMA and CHMP are based on clinical studies, which demonstrated an increase in immune response in participants who were given the booster dose. These participants had already completed a primary two-dose vaccine regimen with Vaxzevria or mRNA-based vaccines approved for use in the European Union (EU).
In the year so far, shares of AstraZeneca have risen 14% compared with the industry’s 5.1% increase.
Image Source: Zacks Investment Research
Excluding the EU, AstraZeneca’s COVID-19 vaccine, either as a primary regimen or a booster dose or both, is already authorized for use in multiple countries across the globe. In fact, the primary vaccine series of the vaccine is granted authorization in more than 125 countries. However, AZN is yet to make a regulatory filing for Vaxzevria in the United States.
Last November, in the United States, the first booster doses of Pfizer/BioNTech and Moderna’s vaccines were granted an EUA for all adults (18 years of age and older). Later, Pfizer/BioNTech’s EUA was extended to allow the dosage in individuals aged 16-17 years and thereafter in adolescents varying from 12 years to 15 years of age. Last week, the Pfizer/BioNTech vaccine was also granted an EUA for use in kids between 5 years and 11 years of age.
In March this year, the FDA authorized a second booster dose of Pfizer/BioNTech and Moderna’s vaccines for older adults and some immunocompromised people. Pfizer/BioNTech and Moderna’s booster shots are authorized for use in adults in Europe.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here